Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium.

[1]  P. Pasdois,et al.  The role of the mitochondrial permeability transition pore in heart disease. , 2009, Biochimica et biophysica acta.

[2]  P. Oliveira,et al.  Doxorubicin increases the susceptibility of brain mitochondria to Ca(2+)-induced permeability transition and oxidative damage. , 2008, Free radical biology & medicine.

[3]  L. Matsubara,et al.  Anthracycline-induced cardiotoxicity. , 2008, Cardiovascular & hematological agents in medicinal chemistry.

[4]  R. Margreiter,et al.  Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells , 2008, Nature Protocols.

[5]  K. Wallace.  Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis , 2007, Cardiovascular Toxicology.

[6]  P. Bernardi,et al.  The mitochondrial permeability transition pore. , 2007, Novartis Foundation symposium.

[7]  T. Wallimann,et al.  New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. , 2006, Journal of molecular and cellular cardiology.

[8]  R. Favory,et al.  Myocardial dysfunction and potential cardiac hypoxia in rats induced by carbon monoxide inhalation. , 2006, American journal of respiratory and critical care medicine.

[9]  R. Favory,et al.  Inhibition of mitochondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. , 2006, Journal of the American College of Cardiology.

[10]  K. Wallace,et al.  Adriamycin-induced oxidative mitochondrial cardiotoxicity , 2006, Cell Biology and Toxicology.

[11]  T. Wallimann,et al.  Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. , 2005, American journal of physiology. Heart and circulatory physiology.

[12]  P. Oliveira,et al.  Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? , 2005, Current vascular pharmacology.

[13]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[14]  S. Javadov,et al.  Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. , 2004, Cardiovascular research.

[15]  E. Voest,et al.  Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. , 2001, European journal of pharmacology.

[16]  Shaoyu Zhou,et al.  Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. , 2001, Cancer research.

[17]  A. Harken,et al.  Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. , 1999, Critical care medicine.

[18]  Hung-Yi Wu,et al.  Molecular Mechanisms of Doxorubicin-induced Cardiomyopathy , 1997, The Journal of Biological Chemistry.

[19]  K. Wallace,et al.  Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. , 1996, Journal of molecular and cellular cardiology.

[20]  A. Allen,et al.  The cardiotoxicity of chemotherapeutic drugs. , 1992, Seminars in oncology.

[21]  U. Andersson,et al.  Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. , 1992, Immunology.

[22]  G. Krishna,et al.  Daunomycin inhibits the uptake of adenine, amino acids, and glucose into cardiac myocytes. , 1987, Toxicology and applied pharmacology.